Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Neurofilament light chain level is a weak risk factor for the development of MS

  • Arrambide, Georgina|||0000-0002-2657-5510
  • Espejo, Carmen|||0000-0001-9949-5901
  • Eixarch, Herena|||0000-0001-7525-9533
  • Villar, Luisa M.|||0000-0002-9067-3668
  • Alvarez-Cermeño, José C.|||0000-0002-1345-2837
  • Picón, Carmen
  • Kuhle, Jens|||0000-0002-6963-8892
  • Disanto, Giulio
  • Kappos, Ludwig|||0000-0003-4175-5509
  • Sastre-Garriga, Jaume|||0000-0002-1589-2254
  • Pareto, Deborah|||0000-0001-7356-3769
  • Simon, Eva
  • Comabella López, Manuel|||0000-0002-2373-6657
  • Río, Jordi|||0000-0003-4546-7627
  • Nos, Carlos|||0000-0002-3830-4910
  • Tur, Carmen|||0000-0003-1849-3184
  • Castilló, Joaquín|||0000-0002-8951-6315
  • Vidal-Jordana, Angela|||0000-0002-7270-5507
  • Galan, Ingrid|||0000-0001-5774-4260
  • Arévalo, María Jesús|||0000-0003-0626-5555
  • Auger, Cristina|||0000-0001-9846-4767
  • Rovira, Alex|||0000-0002-2132-6750
  • Montalban, Xavier|||0000-0002-0098-9918
  • Tintoré, Mar|||0000-0001-9999-5359
To determine the prognostic value of selected biomarkers in clinically isolated syndromes (CIS) for conversion to multiple sclerosis (MS) and disability accrual. Data were acquired from 2 CIS cohorts. The screening phase evaluated patients developing clinically definite MS (CIS-CDMS) and patients who remained as CIS during a 2-year minimum follow-up (CIS-CIS). We determined levels of neurofascin, semaphorin 3A, fetuin A, glial fibrillary acidic protein, and neurofilament light (NfL) and heavy chains in CSF (estimated mean [95% confidence interval; CI]). We evaluated associations between biomarker levels, conversion, disability, and magnetic resonance parameters. In the replication phase, we determined NfL levels (n = 155) using a 900 ng/L cutoff. Primary endpoints in uni- and multivariate analyses were CDMS and 2010 McDonald MS. The only biomarker showing significant differences in the screening was NfL (CIS-CDMS 1,553.1 [1,208.7-1,897.5] ng/L and CIS-CIS 499.0 [168.8-829.2] ng/L, p < 0.0001). The strongest associations were with brain parenchymal fraction change (r = -0.892) and percentage brain volume change (r = -0.842) at 5 years. NfL did not correlate with disability. In the replication phase, more NfL-positive patients, according to the cutoff, evolved to MS. Every 100-ng/L increase in NfL predicted CDMS (hazard ratio [HR] = 1.009, 95% CI 1.005-1.014) and McDonald MS (HR = 1.009, 95% CI 1.005-1.013), remaining significant for CDMS in the multivariate analysis (adjusted HR = 1.005, 95% CI 1.000-1.011). This risk was lower than the presence of oligoclonal bands or T2 lesions. NfL is a weak independent risk factor for MS. Its role as an axonal damage biomarker may be more relevant as suggested by its association with medium-term brain volume changes.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Clinical and Histopathological Amelioration of Experimental Autoimmune Encephalomyelitis by AAV Vectors Expressing a Soluble Interleukin-23 Receptor

  • Miralles, Marta
  • Eixarch, Herena|||0000-0001-7525-9533
  • Tejero Ambrosio, Marcos
  • Costa, Carme|||0000-0001-9577-3839
  • Hirota, Keiji
  • Castaño, Ángel Raúl|||0000-0003-2107-8862
  • Puig Ferrer, Meritxell
  • Stockinger, Gitta
  • Montalban, Xavier|||0000-0002-0098-9918
  • Bosch i Merino, Assumpció|||0000-0002-7205-2796
  • Espejo, Carmen|||0000-0001-9949-5901
  • Chillón Rodríguez, Miguel|||0000-0003-0840-2111
The role of the T helper (Th)17 pathway has been clearly demonstrated in the onset and progression of autoimmune diseases, where interleukin (IL)-23 is a key molecule in maintaining the response mediated by Th17 cells. As a consequence, recent strategies based on blocking the interaction between IL-23 and its receptor (IL-23R), for example the anti-p19 antibody tildrakizumab, have been developed to regulate the Th17 pathway from the initial stages of the disease. Here, a soluble (s)IL-23R cDNA was cloned in expression plasmids and viral vectors. The clinical efficacy of sIL-23R was evaluated in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis mice intravenously injected with a single dose of adeno-associated virus AAV8- sIL-23R vectors. Cytokine secretion was determined by multiplexassay, while histopathological analysis of the central nervous system was performed to study demyelination, inflammatory infiltration, and microglia and astroglia activation. We observed that administration of adeno-associated vector 8 encoding sIL-23R was associated with a significant disease improvement,including delay in the onset of the clinical signs; slower progress of the disease;interference with IL-23- mediated signal transducer and activator of transcription response by inhibiting of signal transducer and activator of transcription 3 phosphorylation; reduced demyelination and infiltration in the central nervous system; and lower astrocyte and microglia activation. Our results suggest that the use of vectors carrying sIL-23R to block the IL-23/IL-23R interaction may be a new therapeutic strategy for the treatment of multiple sclerosis., The online version of this article (doi:10.1007/s13311-017-0545-8) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Lesion topographies in multiple sclerosis diagnosis

  • Arrambide, Georgina|||0000-0002-2657-5510
  • Tintoré, Mar|||0000-0001-9999-5359
  • Auger, Cristina|||0000-0001-9846-4767
  • Río, Jordi|||0000-0003-4546-7627
  • Castilló, Joaquín|||0000-0002-8951-6315
  • Vidal-Jordana, Angela|||0000-0002-7270-5507
  • Galan, Ingrid|||0000-0001-5774-4260
  • Nos, Carlos|||0000-0002-3830-4910
  • Comabella López, Manuel|||0000-0002-2373-6657
  • Mitjana, Raquel|||0000-0002-2076-9461
  • Mulero, Patricia|||0000-0001-8716-8997
  • de Barros, Andrea
  • Rodríguez Acevedo, Breogán|||0000-0002-0314-753X
  • Midaglia, Luciana|||0000-0001-7981-2228
  • Sastre-Garriga, Jaume|||0000-0002-1589-2254
  • Rovira, Alex|||0000-0002-2132-6750
  • Montalban, Xavier|||0000-0002-0098-9918
To assess the contributions of cortico-juxtacortical and corpus callosum lesions to multiple sclerosis diagnosis and to compare the value of ≥1 vs ≥3 periventricular lesions in clinically isolated syndromes (CIS). Step 1: We evaluated lesion topography classifications in 657 patients with CIS with stepwise Cox proportional hazards regression models considering second attack as the outcome. Step 2: We established 2 dissemination in space (DIS) versions according to the periventricular lesion cutoffs of ≥1 and ≥3 and assessed their performance at 10 years with second attack as the outcome, first individually and then combined with dissemination in time (DIT) in all cases (n = 326), by age, and by CIS topography. Step 1: The models (hazard ratios [95% confidence interval]) favored ≥1 over ≥3 periventricular lesions (2.5 [1.7-3.6]) and cortico-juxtacortical over juxtacortical lesions (1.4 [1.0-1.8]). Callosal lesions were not selected. Step 2: DIS specificity with ≥1 periventricular lesions was slightly lower than with ≥3 (59.1 vs 61.4) and the same after adding DIT (88.6). Regarding age, ≥3 periventricular lesions improved DIS specificity over ≥1 lesions in the 40-49 years of age bracket (66.7 vs 58.3). This difference disappeared when adding DIT (83.3). Optic neuritis had a similar pattern when evaluating CIS topographies. Our results comply with the Magnetic Resonance Imaging in Multiple Sclerosis (MAGNIMS) consensus recommendation of combining cortical and juxtacortical lesions into a single term when possible. Concerning periventricular lesions, maintaining the current ≥1 cutoff in the McDonald criteria does not compromise specificity in typical CIS cases, but attention should be paid to older patients or optic neuritis cases.